BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) EBIT

: $-0.47 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

BioForce Nanosciences Holdings's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioForce Nanosciences Holdings's annualized ROC % for the quarter that ended in Dec. 2023 was -29.53%. BioForce Nanosciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioForce Nanosciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -0.93%.

BioForce Nanosciences Holdings EBIT Historical Data

The historical data trend for BioForce Nanosciences Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioForce Nanosciences Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-0.05

-158.41

-0.50

-0.49

-0.47

BioForce Nanosciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT																-0.12	-0.13	-0.11	-0.11	-0.11

Competitive Comparison

For the Packaged Foods subindustry, BioForce Nanosciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioForce Nanosciences Holdings EV-to-EBIT Distribution

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioForce Nanosciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioForce Nanosciences Holdings's EV-to-EBIT falls into.

BioForce Nanosciences Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47 Mil.

BioForce Nanosciences Holdings (OTCPK:BFNH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioForce Nanosciences Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-0.456 * ( 1 - 0% )	/	( (1.491	+	1.597)	/ 2 )
=	-0.456	/	1.544
=	-29.53 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.001	-	0.215	-	( 0.001	-	max(0, 1.706	-	0.001	+	0.001	))
=	1.491

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.001	-	0.223	-	( 0.001	-	max(0, 1.82	-	0.001	+	0.001	))
=	1.597

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

BioForce Nanosciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.456	/	( ( (0 + max(-1.706, 0))	+	(0 + max(-1.82, 0)) )	/	2 )
=	-0.456	/	( ( 0	+	0 )	/	2 )
=	-0.456	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.215	+	0	+	1.491)
=	-1.706

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.223	+	0	+	1.597)
=	-1.82

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioForce Nanosciences Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-0.472	/	50.932
	=	-0.93 %

BioForce Nanosciences Holdings EBIT Related Terms

Thank you for viewing the detailed overview of BioForce Nanosciences Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioForce Nanosciences Holdings Inc (OTCPK:BFNH) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2020 General Booth Boulevard, Suite 230, Virginia Beach, VA, USA, 23454

Website

http://www.bioforceeclipse.com

BioForce Nanosciences Holdings Inc is a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages. It markets its products through social media and telemarketing.

Executives

Richard Kaiser Kaiser	director, 10 percent owner, officer: Secretary/Acting CFO	3419 VIRGINIA BEACH BLVD, UNIT 252, VIRGINIA BEACH VA 23452
Merle Ferguson	director, 10 percent owner, officer: CEO/President/Treasurer	2020 GENERAL BOOTH BLVD., SUITE 230, VIRGINIA BEACH VA 23454
Susan Donohue	10 percent owner	19001 S. RICHFIELD AVE, #102, GREEN VALLEY AZ 85614
Michael D Dunham	director	12000 W PARK PL, EFFECTIVE MANAGEMENT SYSTEMS INC, MILWAUKEE WI 53224
Gregory D Brown	officer: Chief Financial Officer	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010-8098
Kerry M Frey	officer: Chief Operating Officer	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010
Eric Henderson	director, 10 percent owner	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010
Lawrence Marshall Gold	director	830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jean-jacques Sunier	director	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010
Societe Generale Asset Management Alternative Investments	10 percent owner	170, PLACE HENRI REGNAULT, LADEFENSE, PARIS I0 92043
Ed Cowle	10 percent owner	6 EAST 45TH ST., SUITE 1000, NEW YORK NY 10017
H Deworth Williams	10 percent owner	2681 EAST PARLEYS WAY, SUITE #204, SALT LAKE CITY UT 84109
Carter Robert P Iii	10 percent owner	25 RADCLIFFE DRIVE, VOORHEES NJ 08043
Harvey N Kaye	10 percent owner	190 NW SPANISH RIVER BLVD., SUITE 101, BOCA RATON FL 33431

BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Headlines

No Headlines